Graves' disease linked to epstein-barr virus
Part of Eyes & vision, Hormones & metabolism, Immune system & allergy, Infections clinical trials.
This study is looking at whether the Epstein-Barr virus (the virus that causes mono) might trigger or worsen Graves' disease, a condition where the thyroid makes too much hormone. If you have Graves' disease and a history of EBV, this research may help doctors understand the connection and potentially improve treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with Graves' disease, a condition where the thyroid makes too much hormone.
- You have had an Epstein-Barr virus (EBV) infection (the virus that causes mono) recently or in the past.
- You do not have other thyroid problems that can cause high thyroid levels, like thyroiditis, nodules, or medication-related causes.
- You do not have diabetes, other infections, chronic diseases, or cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares different treatment plans to see how well they control Graves’ disease and whether it comes back. It may help by identifying which approach works best to prevent relapse.
This trial tests a new treatment called BHV-1300 for people with Graves' disease. It aims to see if the drug is safe and works well. If you have Graves' disease confirmed by blood tests, you may be able to join.
This study tests efgartigimod, a new medicine given by injection under the skin, to see if it can help control Graves' disease (an overactive thyroid condition). The goal is to reduce the need for other thyroid medications or help people stop taking them.
This trial tests an investigational drug called IMVT-1402 for people with Graves' disease whose thyroid is still overactive even while taking standard antithyroid medication. The goal is to see if the drug can better control thyroid hormone levels.
This study tests a new medicine, BHV-1300, to see if it can safely and effectively reduce the overactive thyroid caused by Graves' disease, an autoimmune condition. It may offer a new option for people who haven't had certain prior treatments.
This study looks at people newly diagnosed with Graves' disease to see who might develop thyroid eye disease, a condition that can affect the eyes. It aims to find early signs so that treatment can be started sooner.
Hear when a new Graves Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.